The Valley of Death in anticancer drug development: a reassessment.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  TIPS - Trends in Pharmacological Sciences

• Publication date

  2012-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.tips.2012.02.001PMID 22410081PMCID PMC3324971
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

  2011cited by this paper
• Wireless Implantable Electronic Platform for Chronic Fluorescent-Based Biosensors

  2011cited by this paper
• The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.

  2011cited by this paper
• How were new medicines discovered?

  2011cited by this paper
• Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

  2011cited by this paper
• Molecular Imaging of Hypoxia

  2011influential reference
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

  2011cited by this paper
• Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.

  2011cited by this paper
• Interfering with pH regulation in tumours as a therapeutic strategy

  2011cited by this paper
• The impact of mergers on pharmaceutical R&D

  2011cited by this paper
• First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

  2011cited by this paper
• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  2011cited by this paper
• NCATS Could Mitigate Pharma Valley of Death

  2011cited by this paper
• Upcoming battles in the war on cancer.

  2011cited by this paper
• Imaging pH with hyperpolarized 13C

  2011cited by this paper
• Salinomycin Selectively Targets ‘CD133+’ Cell Subpopulations and Decreases Malignant Traits in Colorectal Cancer Lines

  2011cited by this paper
• Mouse models of cancer.

  2011cited by this paper
• Probing the links between in vitro potency, ADMET and physicochemical parameters

  2011cited by this paper
• Targeting hypoxia in cancer therapy

  2011cited by this paper
• Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization.

  2011cited by this paper
• Applications of molecular imaging in drug discovery and development process.

  2011cited by this paper
• The APL paradigm and the "co-clinical trial" project.

  2011cited by this paper
• Theranostics: combining imaging and therapy.

  2011cited by this paper
• Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer.

  2011cited by this paper
• Salinomycin inhibits osteosarcoma by targeting its tumor stem cells.

  2011cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

  2011cited by this paper
• Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

  2011cited by this paper
• Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells

  2011cited by this paper
• Bio-inspired, bioengineered and biomimetic drug delivery carriers

  2011cited by this paper
• Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells.

  2011cited by this paper
• Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells.

  2011cited by this paper
• Tumor physiology and charge dynamics of anticancer drugs: implications for camptothecin-based drug development.

  2011cited by this paper
• Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences?

  2011cited by this paper
• Hedgehog Signaling: Networking to Nurture a Promalignant Tumor Microenvironment

  2011cited by this paper
• The productivity crisis in pharmaceutical R&D

  2011cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  2010cited by this paper
• How to improve R&D productivity: the pharmaceutical industry's grand challenge

  2010cited by this paper
• The war on cancer: have we won the battle but lost the war?

  2010cited by this paper
• Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment.

  2010cited by this paper
• Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo

  2010cited by this paper
• Nanomedicine strategies for molecular targets with MRI and optical imaging.

  2010cited by this paper
• Anticancer drug development: the grand challenges

  2010cited by this paper
• Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring.

  2010cited by this paper
• Implantable semiconductor biosensor for continuous in vivo sensing of far-red fluorescent molecules.

  2010cited by this paper
• The assessment of microvascular flow and tissue perfusion using ultrasound imaging

  2010cited by this paper
• Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common chemotherapeutic drugs

  2010cited by this paper
• Envisioning the future of early anticancer drug development

  2010cited by this paper
• At a crossroads in oncology.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• Therapeutic drug monitoring in cancer chemotherapy.

  2010cited by this paper
• The altered metabolism of tumors: HIF-1 and its role in the Warburg effect.

  2010cited by this paper
• The hematopoietic stem cell niche: Low in oxygen but a nice place to be

  2010cited by this paper
• Hypoxia or in situ normoxia: The stem cell paradigm

  2009cited by this paper
• Traversing the Valley of Death: A Guide to Assessing Prospects for Translational Success

  2009cited by this paper
• Unpatentable Drugs and the Standards of Patentability

  2009cited by this paper
• The future of drug development: advancing clinical trial design

  2009cited by this paper
• Camptothecin and Fas receptor agonists synergistically induce medulloblastoma cell death: ROS-dependent mechanisms

  2009cited by this paper
• β-Arrestin–Biased Parathyroid Hormone Ligands: A New Approach to the Development of Agents that Stimulate Bone Formation

  2009cited by this paper
• Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

  2009cited by this paper
• Why animal studies are often poor predictors of human reactions to exposure

  2009cited by this paper
• Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1α Axis

  2009cited by this paper
• Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.

  2009cited by this paper
• Identification of selective inhibitors of cancer stem cells by high-throughput screening.

  2009cited by this paper
• Assessing the translatability of drug projects: what needs to be scored to predict success?

  2009cited by this paper
• Drug exposure: still an excellent biomarker.

  2009cited by this paper
• Phase 0 clinical trials: an answer to drug development stagnation?

  2009cited by this paper
• Molecular Imaging of Hypoxia

  2008cited by this paper
• Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1α and -2α

  2008cited by this paper
• Translational research: Crossing the valley of death

  2008cited by this paper
• The meaning of translational research and why it matters.

  2008cited by this paper
• The observed variance between predicted and measured radiation dose in breast and prostate patients utilizing an in vivo dosimeter.

  2008cited by this paper
• We fought cancer...and cancer won.

  2008cited by this paper
• Therapeutic drug monitoring of cancer chemotherapy

  2007cited by this paper
• Why is cancer drug discovery so difficult?

  2007cited by this paper
• Biomarkers in Phase I Oncology Trials: Signal, Noise, or Expensive Distraction?

  2007cited by this paper
• Compressing drug development timelines in oncology using phase '0' trials

  2007cited by this paper
• Detection and Characterization of Tumor Hypoxia Using pO2 Histography

  2007cited by this paper
• Optimizing combination chemotherapy by controlling drug ratios.

  2007cited by this paper
• Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics

  2006cited by this paper
• Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice

  2006cited by this paper
• Analysis: Overcoming the "Valley of Death": Mouse Models to Accelerate Translational Research

  2006cited by this paper
• Drug discovery in jeopardy.

  2006cited by this paper
• Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1α)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells

  2005cited by this paper
• What's wrong with our cancer models?

  2005cited by this paper
• The rise and rise of drug delivery

  2005cited by this paper
• Culturing at atmospheric oxygen levels impacts lymphocyte function.

  2005cited by this paper
• The effect of Topotecan on oxidative stress in MCF-7 human breast cancer cell line.

  2005cited by this paper
• Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient

  2005cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004influential reference
• Why we're losing the war on cancer (and how to win it).

  2004cited by this paper
• ADMET in silico modelling: towards prediction paradise?

  2003cited by this paper
• Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents.

  2003cited by this paper
• Comparative biology of mouse versus human cells: modelling human cancer in mice

  2003cited by this paper
• Understanding the tumor metabolic phenotype in the genomic era.

  2003cited by this paper
• Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro.

  2003cited by this paper
• How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development.

  2003cited by this paper
• Pharmacokinetically Guided Administration of Chemotherapeutic Agents

  2000cited by this paper
• A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect

  2000cited by this paper
• Concordance of the toxicity of pharmaceuticals in humans and in animals.

  2000cited by this paper
• 19F-MRS studies of fluorinated drugs in humans.

  2000cited by this paper

• Role of Patient-Derived Tumor Organoids in Advanced Cancer Research.

  2025cites this paper
• ヒト食道扁平上皮がんオルガノイドモデルの確立

  2025cites this paper
• Advances in Near-Infrared BODIPY Photosensitizers: Design Strategies and Applications in Photodynamic and Photothermal Therapy

  2025cites this paper
• DRPMKB1.0: A Comprehensive Knowledge Base for an AI-Oriented Drug Repositioning Prediction Model

  2025cites this paper
• In silico design and evaluation of a hydrophobic-hydrophilic combinatorial drug systems for targeted breast cancer therapy.

  2025cites this paper
• Immuno‐Engineering in the AI Era: From Fundamental Research to Clinical Translation

  2025cites this paper
• Unlocking the Potential of Camel Milk-Derived Exosomes as Novel Delivery Systems: Enhanced Bioavailability of ARV-825 PROTAC for Cancer Therapy

  2024cites this paper
• Molecular Pharmacology of Dasatinib Provides Unique Insights into the Mechanistic Basis of Success and Failure of Targeted Cancer Therapy.

  2024cites this paper
• Nanoparticles for Cancer Gene Therapy and Imaging

  2024cites this paper
• Nanomedicines: Nano based Drug Delivery Systems Challenges and Future of nanomedicines

  2024cites this paper
• Multitask Learning on Graph Convolutional Residual Neural Networks for Screening of Multitarget Anticancer Compounds

  2024cites this paper
• Drug-Drug Interactions and Synergy: From Pharmacological Models to Clinical Application

  2024cites this paper
• Towards a better preclinical cancer model – human immune aging in humanized mice

  2023cites this paper
• Nanomedicine-fortified cosmeceutical serums for the mitigation of psoriasis and acne.

  2023cites this paper
• Genetic models of fibrillinopathies

  2023cites this paper
• Converting inventions into innovations to address cancer grand challenges: The role of scientific and digital search intensity

  2023cites this paper
• Amorphous Solid Dispersion as Drug Delivery Vehicles in Cancer

  2023cites this paper
• Polysaccharide-based nanoassemblies: From synthesis methodologies and industrial applications to future prospects.

  2023cites this paper
• Cancer Care by Committee to be Superseded by Personal Physician–Patient Partnership Informed by Artificial Intelligence

  2023cites this paper
• Conditional lethality profiling reveals anticancer mechanisms of action and drug-nutrient interactions

  2023cites this paper
• Key aspects for conception and construction of co-culture models of tumor-stroma interactions

  2023cites this paper
• Targeting Wnt/tenascin C-mediated cross talk between pancreatic cancer cells and stellate cells via activation of the metastasis suppressor NDRG1

  2022cites this paper
• Recent Updates on the Development of Deuterium-Containing Drugs for the Treatment of Cancer

  2022cites this paper
• Chemotherapeutics and CAR‐T Cell‐Based Immunotherapeutics Screening on a 3D Bioprinted Vascularized Breast Tumor Model

  2022cites this paper
• Real-time monitoring of oxygen levels within thermoplastic organ-on-chip devices

  2022cites this paper
• Progressing Towards a Human-Centric Approach in Cancer Research

  2022cites this paper
• Design, Synthesis, and Anti-Inflammatory Activity of Some Coumarin Schiff Base Derivatives: In silico and in vitro Study

  2022cites this paper
• Radiotheranostics in oncology: current challenges and emerging opportunities

  2022cites this paper
• Utilizing Three-Dimensional Culture Methods to Improve High-Throughput Drug Screening in Anaplastic Thyroid Carcinoma

  2022cites this paper
• 3D Bioprinted perfusable and vascularized breast tumor model for dynamic screening of chemotherapeutics and CAR-T cells

  2022cites this paper
• Research and Development Investment of Would-Be Star Biotech Firms in a Financial Crisis

  2022cites this paper
• iANP-EC: Identifying Anticancer Natural Products Using Ensemble Learning Incorporated with Evolutionary Computation

  2022cites this paper
• Investigating oxygen transport efficiencies in precision-cut liver slice-based organ-on-a-chip devices

  2021cites this paper
• 5FU encapsulated polyglycerol sebacate nanoparticles as anti-cancer drug carriers

  2021cites this paper
• Regulatory perspectives of nanomedicines for cancer treatment

  2021cites this paper
• Moving drug discoveries beyond the valley of death: the role of innovation ecosystems

  2020cites this paper
• Nanomedicines: Redefining traditional medicine.

  2020cites this paper
• Senescence and the Impact on Biodistribution of Different Nanosystems: the Discrepancy on Tissue Deposition of Graphene Quantum Dots, Polycaprolactone Nanoparticle and Magnetic Mesoporous Silica Nanoparticles in Young and Elder Animals

  2020cites this paper
• Nanomedicines: Nano based Drug Delivery Systems Challenges and Opportunities

  2020cites this paper
• Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions.

  2020cites this paper
• Industrial perspectives and future of oral drug delivery

  2020cites this paper
• Bridging the Valley of Death: Lessons from an Entrepreneurial Program

  2020cites this paper
• Nanomedicines for cancer therapy: current status, challenges and future prospects.

  2019cites this paper
• Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.

  2019cites this paper
• Cancer drug development: The missing links

  2019cites this paper
• Multicomponent access to novel proline/cyclized cysteine tethered monastrol conjugates as potential anticancer agents

  2019cites this paper
• Rapid and sensitive electrochemical detection of anticancer effects of curcumin on human glioblastoma cells

  2019cites this paper
• Bioactivity-Guided Fractionation for Anti-Cancer Property of Leaves of Justicia beddomei

  2019cites this paper
• Ene-Reductases in Pharmaceutical Chemistry

  2019cites this paper
• Pacifastin-derived Peptides Target Tumors for Use in In Vivo Imaging.

  2018cites this paper
• Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor explants

  2018cites this paper
• Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer

  2018cites this paper
• Where are the drought tolerant crops? An assessment of more than two decades of plant biotechnology effort in crop improvement.

  2018cites this paper
• Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants *

  2018cites this paper
• New pharmacokinetic and PK/PD drug development methodologies for cutaneous leishmaniasis

  2018cites this paper
• Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism

  2017cites this paper
• Crossing the Valley of Death : exploring commercialization of food startups in Switzerland

  2017cites this paper
• Lessons Learned from Two Decades of Anticancer Drugs.

  2017cites this paper
• A Plutocratic Proposal: an ethical way for rich patients to pay for a place on a clinical trial

  2017cites this paper
• Identification of licofelone through three-dimensional cell culture drug screening as a repurposed agent able to reverse drug resistant and cancer stem cell-like subpopulations in ovarian cancer

  2017cites this paper
• Overview of Research and Development for Anticancer Drugs

  2016cites this paper
• Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging

  2016cites this paper
• Exploring the Valley of Death in Biopharma

  2016influential citation
• Effect of molecular markers HIF-1α and IDH1 on the radiobiological behavior of human malignant glioma cell lines in normoxia and hypoxia

  2016cites this paper
• Marine Mollusk‐Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance

  2016cites this paper
• Challenges of clinical translation in nanomedicine: A qualitative study.

  2016cites this paper
• Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer

  2016cites this paper
• Mouse models of human disease

  2016cites this paper
• Mouse models of human disease evolutionary perspective

  2016cites this paper
• Ultrashort cationic lipopeptides and lipopeptoids: Evaluation and mechanistic insights against epithelial cancer cells.

  2016cites this paper
• Translational medicine and its perspectives in Poland

  2016cites this paper
• Does age matter? The impact of rodent age on study outcomes

  2016cites this paper
• An efficient injectable formulation with block copolymer micelles for hydrophobic antitumor candidate-pyridazinone derivatives.

  2015cites this paper
• Le point de vue du sociologue sur la recherche translationnelle à partir du cas de la cancérologie

  2015cites this paper
• Design of small-molecule inhibitors of sulfatase 2 and ERK5

  2015cites this paper
• Phytocannabinoids for Cancer Therapeutics: Recent Updates and Future Prospects.

  2015cites this paper
• Delta9‐tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: A critical examination of the preclinical literature

  2015cites this paper
• Data Analytics for Pharmaceutical Discoveries

  2015cites this paper
• A method to investigate the anti-metabolic activity of anti-cancer agents on ovarian cancer cells cultured in a 96-well high throughput format

  2015cites this paper
• Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials

  2015cites this paper
• Integrated Computational and Experimental Approaches for Accelerated Drug Combination Discovery and Development : Applications in Cancer Pharmacology

  2015cites this paper
• Production of drug-loaded polymeric nanoparticles by electrospraying technology.

  2014cites this paper
• Nanotoxicology: Towards Safety by Design

  2014cites this paper
• A Multilayered Cell Culture Model for Transport Study in Solid Tumors: Evaluation of Tissue Penetration of Polyethyleneimine Based Cationic Micelles.

  2014cites this paper
• Cell-based drug testing; this world is not flat.

  2014cites this paper
• The influence of monoacylglycerol lipase inhibition upon the expression of epidermal growth factor receptor in human PC-3 prostate cancer cells

  2014cites this paper
• Tropism of the in situ growth from biopsies of childhood neuroectodermal tumors following transplantation into experimental teratoma

  2014cites this paper
• Chapter 1 Data Analytics for Pharmaceutical Discoveries

  2014cites this paper
• Alternative Models in Drug Discovery and Development Part I: In Silico and In Vitro Models

  2014cites this paper
• Anticipating Market Introduction of Nanotechnology-Enabled Drug Delivery Systems

  2014cites this paper
• Parallel universes of Black Six biology

  2014influential citation
• Deadly gaps in the patent system : an analysis of currentand alternative mechanisms for incentivising development of medical therapies.

  2014cites this paper
• Ex vivo culture of human prostate tissue and drug development

  2013cites this paper
• Nanoparticles targeting mechanisms in cancer therapy: current limitations and emerging solutions.

  2013cites this paper
• How can attrition rates be reduced in cancer drug discovery?

  2013cites this paper
• In vitro chemo-sensitivity assay guided chemotherapy is associated with prolonged overall survival in cancer patients.

  2013cites this paper
• Nanoparticles targeting mechanisms in cancer therapy; great efforts, less implementations.

  2013cites this paper
• NIPTE: a multi-university partnership supporting academic drug development.

  2013cites this paper
• Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.

  2013cites this paper
• Advances in translational pharmacological investigations in identifying and validating molecular targets of natural product anticancer agents.

  2013cites this paper